臺灣博碩士論文加值系統

第一線目前用於治療結核病（TB）感染的藥物有streptomycin，isoniazid (INH)，ethambutol，pyrazinamide，rifampicin。然而，目前的結核病治療方案，雖然高效，但還是不夠理想。近來，出現多重耐藥性（MDR）菌株和全球性的人類免疫缺陷病毒（HIV）的流行創造了結核分枝桿菌感染的替代藥物治療的迫切需要。在過去的幾年中，我們一直特別感興趣的如茚[1,2-c]喹啉，吲哚[2,3-b]喹啉，苯并呋喃[2,3-b]喹啉衍生物的合成被用來抗結核和抗癌的活性評估。
本論文介紹了合成一些茚[1,2-c]喹啉衍生物對於抗結核菌進行活性評估。其中，化合物40c表現出了最低抑菌濃度（MIC）<0.5?慊/mL比一線藥物INH（MIC = 0.8 - 1.2?慊/mL）更要優越。化合物40c屬於一種新型的結構，另外被發現不會抑制Vero細胞的生長，因此，很有潛力可以作為一種新型抗結核病藥物。

The first-line drugs currently used for the treatment of tuberculosis (TB) infection are streptomycin, isoniazid (INH), ethambutol, pyrazinamide, and rifampicin. However, the current TB treatment regimens, although highly effective, are far from ideal. Recently, the emergence of multi-drug resistant (MDR) strains and the global human immunodeficiency virus (HIV) pandemic have created an urgent need for alternative drug treatments for Mycobacterium tuberculosis infection. Over the past few years, we have been particularly interested in the synthesis of condensed quinolines such as indeno[1,2-c]quinoline, indolo[2,3-b]quinoline, and benzofuro[2,3-b]quinoline derivatives for anti-TB and anticancer evaluations.
This thesis describes synthesis of certain indeno[1,2-c]quinoline derivatives for anti-TB evaluations. Among them, compound 40c exhibited a minimum inhibitory concentration (MIC) of < 0.5 ?慊/mL which was more active the positive INH (MIC = 0.8 - 1.2 μg/mL). Compound 40c belongs to a novel structure type and was not cytotoxic against the growth of Vero cells and therefore, could serve as a potential lead for the development of novel anti-TB drug candidate.

中文摘要…………………………………………………………1
英文摘要…..…………………………………………………….2
壹、緒論….…..……………………………………....….3
貳、研究背景與動機..…………………………………..8
参、合成方法與步驟.………………………………………12
肆、藥理活性實驗方法與討論…………….…….…..……24
伍、結論….…..……………………………………....….29
陸、實驗部分………….……………………….………30
柒、參考文獻………….……………………….………124
附綠

1. Lin, Y.-M.; Flavin, M. T.; Cassidy, C. S.; Mar A.; Chen F.-C. Biflavonoids as Novel Antituberculosis Agents. Bioorg. Med. Chem. Lett. 2001, 11, 2101–2104.
2. Renau, T. E.; Sanchez, J. P.; Shapiro, M. A.; Dever, J. A.; Gracheck, S. J.; Domagala, J. M. Effect of Lipophilicity at N-1 on Activity of Fluoroquinolones against Mycobacteria. J. Med. Chem. 1995, 38, 2974-2977.
3. Ji, b.; Lounis N.; Chantal T. P.; Gresset, J.; In Vitro and In Vivo Activities of Levofloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1995, 39, 1341-1344.
4. Hooper, D. C. Mechanisms of Action and Resistance of Older and Newer Fluoroquinolones, Clin. Infect. Dis. 2000, 31(suppl. 2): 24-28.
5. Drlica, K.; Zhao, X. DNA Gyrase, Topoisomerase IV, and the
4-Quinolones, Microbiol. Mol. Biol. Rev. 1997, 377-392.
6. Klopman, G.; Fercu, D.; Renau, T. E.; Jacobs, M. R. N-1-tert-Butyl-
Substituted Quinolones: In Vitro Anti-Mycobacterium avium Activities and Structure-ActivityRelationship Studies. Antimicrob. Agents Chemother. 1996, 40, 2637-2643.
7. Andries1, K.; Verhasselt, P.; Guillemont, J.; Gohlmann1, W. H.; Neefs1, J. M..; Winkler1, H.; Gestel, J. V.; Timmerman1, P.; Zhu, M.; Lee, E; Williams, P.; Chaffoy, D.; Huitric, E.; Hoffner, S. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis Science. 2005, 307, 223-227.


8. L. G. Dover.; Coxon, G. D. Current Status and Research Strategies in Tuberculosis Drug Development. J. Med. Chem. 2011, 54, 6157–6165.
9. Tangallapally, R. P.; Yendapally, R.; Lee, R. E.; Hevener, K.; Jones, V. C.; Lenaerts, J. M.; McNeil, M. R.; Wang, Y.; Franzblau, S.; Lee, R. Synthesis and Evaluation of Nitrofuranylamides as Novel Antituberculosis Agents. J. Med. Chem. 2004, 47, 5276–5283.
10. Domıngueza, J. N.; Charrisa, J. E.; Loboa, G.; Sayyed, S.; Domınguezb, N. G.; Morenob, M. M.; Riggionec F. ; Sanchezd, E. ; Olsone, J.; Rosenthale, P. J. Synthesis of quinolinyl chalcones and evaluation of their antimalarial activity. Euro. J. Med. Chem. 2001, 36, 555–560.
11. Ram, S. U.; Santosh, V. L.; Lahore, A. Y.; Sayyed, S. S.; Dixit, D. S.; Jyoti, C. Conformationally-constrained indeno[2,1-c]quinolines – a new class of anti-mycobacterial agents. Org. Biomol. Chem. 2010, 8, 2180–2197.
12. K.D. Thomas.; Airody, V. A.; Telkar, S.; Sayyed, S.; Imran, H. C.; Riaz, M.; Nishith K. P. ; Guru Rowd, E. S. Design, synthesis and docking studies of new quinoline-3-carbohydrazide derivatives as antitubercular agents. Euro. J. Med. Chem. 2011, 46, 5283-5292.
13.Boechat, N; Ferreira, V. F.; Ferreira, S. B.; Lourdes, G. M. Novel 1,2,3-Triazole Derivatives for Use against Mybacterium tuberculosis H37Rv (ATCC 27294) Strain. J. Med. Chem. 2011, 54, 5988-5999.
14. Asao, T.; Okazaki, S.; Wakita, S.; Utsuki, T.; Yamada, Y. Preparation of indenoquinoline derivatives and analogs as antitumor agents. JP 1997,09143166 A2.

15. Anzini, M.; Cappelli, A.; Vomero, S. Synthesis of 6-(4-methyl-1-
piperazinyl)-7H-indeno[2,1-c]quinoline derivatives as potential 5-HT receptor ligands. J.Heterocyclic Chem. 1991, 28, 1809-1812.
16. Xiao, Z.; Waters, N. C.; Woodard C. L.; Li, Z.; Li, P. K. Design and synthesis of pfmrk inhibitors as potential antimalarial agents. Bioorg. Med. Chem. Lett. 2001, 11, 2875-2878.
17. Tseng, C. H.; Chen, Y. L.; Chung, K. Y.; Cheng, C. M.; Wang, C. H.; Tseng, C. C. Synthesis and antiproliferative evaluation of 6-arylindeno
[1,2-c]quinoline derivatives. Bioorg. Med. Chem. 2009, 17, 7465–7476.
18. Borsche, S. Justus Liebigs Ann. Chem. 1937, 532, 146-152.
19. A. L. Collins, G. F. Scott, Antimicrobial Agents and Chemotherapy, 1997, 41, 1004.
20. 郭育綺(2008)蓮子有效成分對於自體性免疫疾病老鼠之免疫藥理 活性評估。中國藥年報，第26期，第2冊，113-158頁。